Literature DB >> 16030291

A novel dopamine agonist for the transdermal treatment of Parkinson's disease.

Peter Jenner1.   

Abstract

Rotigotine is a non-ergot, enantio-selective, D3/D2/D1 dopamine (DA) agonist drug that is effective in classical models of Parkinson's disease (PD), including the reserpinised mouse, the 6-hydroxydopamine-lesioned rat, and the MPTP-treated primate. It is active after oral administration but shows high clearance and a relatively short duration of effect. However, rotigotine is also effective after transdermal application in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, in both of which the duration of effect is markedly enhanced. The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16030291     DOI： 10.1212/wnl.65.2_suppl_1.s3

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

2.  Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.

Authors:  Marina Braun; Jan-Peer Elshoff; Jens-Otto Andreas; Louise Ischen Müller; Rolf Horstmann
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

3.  Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists.

Authors:  Patrick A Randall; Eric J Nunes; Simone L Janniere; Colin M Stopper; Andrew M Farrar; Thomas N Sager; Younis Baqi; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2011-02-24       Impact factor: 4.530

4.  Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

Authors:  Willi Cawello; Andreas Fichtner; Hilmar Boekens; Marina Braun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-20       Impact factor: 2.441

5.  The use of rotigotine in the treatment of restless legs syndrome.

Authors:  Anna Serafini; Simone Lorenzut; Gian Luigi Gigli; Giovanni Merlino; Mariarosaria Valente
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

6.  Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.

Authors:  J Kehr; X-J Hu; M Goiny; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2007-04-16       Impact factor: 3.575

7.  Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.

Authors:  Marina Braun; Willi Cawello; Hilmar Boekens; Rolf Horstmann
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

8.  Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.

Authors:  Willi Cawello; Hans Michael Wolff; Wim J A Meuling; Rolf Horstmann; Marina Braun
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Parkinson's disease: genetics and beyond.

Authors:  N N Inamdar; D K Arulmozhi; A Tandon; S L Bodhankar
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

10.  Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study.

Authors:  Mariano Serrao; Alberto Ranavolo; Carmela Conte; Chiara Davassi; Silvia Mari; Alfonso Fasano; Giorgia Chini; Gianluca Coppola; Francesco Draicchio; Francesco Pierelli
Journal:  J Neurol       Date:  2015-08-25       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.